Wall Street analysts expect that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will report ($0.15) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Achillion Pharmaceuticals’ earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.15). Achillion Pharmaceuticals reported earnings of ($0.17) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 11.8%. The business is scheduled to report its next quarterly earnings results on Thursday, February 28th.
On average, analysts expect that Achillion Pharmaceuticals will report full-year earnings of ($0.52) per share for the current year, with EPS estimates ranging from ($0.53) to ($0.50). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.57) per share, with EPS estimates ranging from ($0.60) to ($0.52). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Achillion Pharmaceuticals.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02.
Several large investors have recently made changes to their positions in ACHN. Acadian Asset Management LLC bought a new position in shares of Achillion Pharmaceuticals during the second quarter valued at $135,000. Cubist Systematic Strategies LLC bought a new position in shares of Achillion Pharmaceuticals during the second quarter valued at $147,000. BlueMountain Capital Management LLC bought a new position in shares of Achillion Pharmaceuticals during the second quarter valued at $159,000. Logan Capital Management Inc. bought a new position in Achillion Pharmaceuticals in the third quarter valued at about $166,000. Finally, MetLife Investment Advisors LLC lifted its holdings in Achillion Pharmaceuticals by 81.0% in the third quarter. MetLife Investment Advisors LLC now owns 101,528 shares of the biopharmaceutical company’s stock valued at $374,000 after acquiring an additional 45,425 shares during the period. 77.61% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:ACHN traded up $0.05 during midday trading on Friday, reaching $2.89. 770,170 shares of the company’s stock traded hands, compared to its average volume of 1,517,464. The company has a market cap of $393.67 million, a P/E ratio of -4.66 and a beta of 1.69. Achillion Pharmaceuticals has a one year low of $2.33 and a one year high of $4.34.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Recommended Story: Earnings Per Share (EPS) Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.